CPT code 86794 represents a laboratory immunoassay to detect immunoglobulin M (IgM) antibodies to Zika virus in patient serum. This test identifies recent or acute Zika virus infection and is an important diagnostic tool for clinical management, public health surveillance, and screening in relevant clinical scenarios. Nationally, accurate coding and coverage of Zika IgM testing affect laboratory workflows, claim adjudication, and reporting during outbreaks.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and medical necessity criteria for Zika IgM testing vary across payers and between commercial and government plans; these differences influence authorization requirements, documentation expectations, and reimbursement pathways.

Readers will find an overview of the clinical purpose of the test, typical sites of service, and common billing considerations. The publication summarizes payer coverage patterns, benchmark metrics where available, and relevant administrative guidance that affects claim processing for this laboratory service. The content also provides clinical context on when IgM testing is used in patient evaluation and public health response. Data not available in the input will be noted where applicable.